

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 August 2005 (04.08.2005)

PCT

(10) International Publication Number  
**WO 2005/071077 A1**

(51) International Patent Classification<sup>7</sup>: C12N 15/10, (74) Agent: BOHMANN, Armin, K.; Bohmann & Loosen,  
15/66, C12P 19/34 Sonnenstr. 8, 80331 Munich (DE).

(21) International Application Number:  
PCT/EP2005/000620

(22) International Filing Date: 22 January 2005 (22.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
04001462.3 23 January 2004 (23.01.2004) EP

(71) Applicant (for all designated States except US):  
SLONING BIOTECHNOLOGY GMBH [DE/DE];  
Zeppelinstr. 4, 82178 Puchheim (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHATZ, Octavian [DE/DE]; Steinbergstrasse 30, 85250 Altomünster (DE). O'CONNELL, Timothy [IE/DE]; Asambogen 48, 82256 Fürstenfeldbruck (DE). HORN, Gudrun [DE/DE]; Herzog-Johann-Strasse 48, D-81245, München (DE). SCHWER, Heinz [DE/DE]; Zugspitzstr. 6, D-86807 Buchloe (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DE NOVO ENZYMATIC PRODUCTION OF NUCLEIC ACID MOLECULES

(57) Abstract: The present invention is related to a method for the manufacture of a nucleic acid molecule comprising the following steps: a) providing a first at least partially double-stranded oligonucleotide, whereby the oligonucleotide comprises a first and a second single-stranded overhang, b) providing a second at least partially double-stranded oligonucleotide, whereby the oligonucleotide comprises a recognition site for a first type IIS restriction enzyme which cuts outside its recognition site, a modification allowing the oligonucleotide to be coupled to a surface and a single-stranded overhang, c) ligating the first oligonucleotide and the second oligonucleotide via the first single-stranded overhang of the first oligonucleotide and the single-stranded overhang of the second oligonucleotide, generating a first ligation product, whereby the first ligation product comprises a single-stranded overhang essentially corresponding to the second single-stranded overhang of the first oligonucleotide, d) cutting the first ligation product with the first type II restriction enzyme thus releasing an elongated first at least partially double-stranded oligonucleotide having a first and a second single-stranded overhang, whereby the first single-stranded overhang is generated through the cutting of the restriction enzyme and whereby the second single-stranded overhang corresponds essentially to the second single-stranded overhang of the first at least partially double-stranded oligonucleotide, preferably the at least partially double-stranded oligonucleotide of step (a), and a truncated second at least partially double-stranded oligonucleotide; e) immobilising the truncated second at least partially double stranded oligonucleotide of step d), the unreacted second at least partially double-stranded oligonucleotide and/or the uncut first ligation product via the modification to a surface; f) optionally repeating steps a) to e), whereby the elongated first at least partially double-stranded oligonucleotide of step d) serves as the first at least partially double-stranded oligonucleotide in step a).

WO 2005/071077 A1